Clinical Research Directory
Browse clinical research sites, groups, and studies.
Efficiency of Imatinib Treatment After 10 Years of Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (Gist-Ten)
Sponsor: Centre Leon Berard
Summary
This is a 2 arms study concerning patients under imatinib treatment for at least 10 years of treatment with locally advanced/metastatic GIST. In the first arm, patients will discontinue Imatinib treatment. This arm will allow to determine if the re-introduction of Imatinib at relapse is still an efficient treatment for the control of disease. In the second arm, patients will continue Imatinib treatment, allowing to determine if the continuation of this treatment is efficient for disease control, by the rate of non-progression disease.
Official title: Randomized, Multicentre, Phase II Study Evaluating the Interest of Imatinib Treatment Maintenance or Interruption After at Least 10 Years of Treatment in Patients With Locally Advanced/Metastatic Gastrointestinal Stromal Tumors (GISTs)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
50
Start Date
2022-01-03
Completion Date
2027-01
Last Updated
2023-09-01
Healthy Volunteers
No
Conditions
Interventions
Imatinib tablets
Imatinib interruption
Locations (13)
CHU Besançon
Besançon, France
Institut Bergonié
Bordeaux, France
CHU Dupuytren
Limoges, France
Centre Léon Bérard
Lyon, France
Institut Paoli Calmettes
Marseille, France
Institut Curie
Paris, France
CHU de Reims
Reims, France
Centre Eugène Marquis
Rennes, France
Institut de Cancérologie de l'Ouest - Site Réné Gauducheau
Saint-Herblain, France
Institut de Cancérologie Lucien NEUWIRTH
Saint-Paul-en-Jarez, France
Institut Claudius Regaud
Toulouse, France
Institut de Cancérologie de Lorraine
Vandœuvre-lès-Nancy, France
Institut Goustave Roussy
Villejuif, France